Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 400

1.

Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.

Leblanc S, Battista MC, Noll C, Hallberg A, Gallo-Payet N, Carpentier AC, Vine DF, Baillargeon JP.

Endocrinology. 2014 Sep;155(9):3684-93. doi: 10.1210/en.2014-1185. Epub 2014 Jun 27.

PMID:
24971613
2.

Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women.

Möhlig M, Weickert MO, Ghadamgadai E, Machlitt A, Pfüller B, Arafat AM, Pfeiffer AF, Schöfl C.

Eur J Endocrinol. 2007 Aug;157(2):195-200.

PMID:
17656598
3.

Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.

Gambineri A, Patton L, De Iasio R, Palladoro F, Pagotto U, Pasquali R.

J Clin Endocrinol Metab. 2007 Jun;92(6):2066-73. Epub 2007 Mar 13.

PMID:
17356050
4.

Role of Lipotoxicity and Contribution of the Renin-Angiotensin System in the Development of Polycystic Ovary Syndrome.

Connolly A, Leblanc S, Baillargeon JP.

Int J Endocrinol. 2018 Jun 3;2018:4315413. doi: 10.1155/2018/4315413. eCollection 2018. Review.

5.

A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome.

Shi D, Dyck MK, Uwiera RR, Russell JC, Proctor SD, Vine DF.

Endocrinology. 2009 Sep;150(9):4425-36. doi: 10.1210/en.2008-1612. Epub 2009 May 21.

PMID:
19470707
6.

Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome.

Mukherjee S, Shaikh N, Khavale S, Shinde G, Meherji P, Shah N, Maitra A.

Eur J Endocrinol. 2009 May;160(5):855-62. doi: 10.1530/EJE-08-0932. Epub 2009 Feb 11.

PMID:
19211708
7.

Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.

Yildiz BO, Yarali H, Oguz H, Bayraktar M.

J Clin Endocrinol Metab. 2003 May;88(5):2031-6.

PMID:
12727950
8.

Discovery of Novel Lipid Profiles in PCOS: Do Insulin and Androgen Oppositely Regulate Bioactive Lipid Production?

Li S, Chu Q, Ma J, Sun Y, Tao T, Huang R, Liao Y, Yue J, Zheng J, Wang L, Xue X, Zhu M, Kang X, Yin H, Liu W.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):810-821. doi: 10.1210/jc.2016-2692.

9.

Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome.

Alemzadeh R, Kichler J, Calhoun M.

Eur J Endocrinol. 2010 Jun;162(6):1093-9. doi: 10.1530/EJE-10-0205. Epub 2010 Apr 6.

PMID:
20371657
10.

Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome.

González F, Rote NS, Minium J, Kirwan JP.

J Clin Endocrinol Metab. 2006 Jan;91(1):336-40. Epub 2005 Oct 25.

PMID:
16249279
11.

Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.

Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD.

J Clin Endocrinol Metab. 2003 Feb;88(2):576-80.

PMID:
12574183
12.

Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome.

Lam UD, Lerchbaum E, Schweighofer N, Trummer O, Eberhard K, Genser B, Pieber TR, Obermayer-Pietsch B.

Gene. 2014 Mar 10;537(2):245-52. doi: 10.1016/j.gene.2013.12.055. Epub 2014 Jan 2.

PMID:
24388959
13.

Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.

Wu J, Zhu Y, Jiang Y, Cao Y.

Gynecol Endocrinol. 2008 Jul;24(7):392-8. doi: 10.1080/09513590802217027.

PMID:
18608522
14.

Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.

Panidis D, Tziomalos K, Misichronis G, Papadakis E, Betsas G, Katsikis I, Macut D.

Hum Reprod. 2012 Feb;27(2):541-9. doi: 10.1093/humrep/der418. Epub 2011 Dec 5.

PMID:
22144419
15.

Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome.

Toscani MK, Mario FM, Radavelli-Bagatini S, Spritzer PM.

Nutr Res. 2011 Feb;31(2):97-103. doi: 10.1016/j.nutres.2011.01.009.

16.
18.

Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance.

Morishita M, Endo T, Baba T, Kuno Y, Ikeda K, Kiya T, Honnma H, Saito T.

J Ovarian Res. 2018 Mar 27;11(1):24. doi: 10.1186/s13048-018-0395-y.

19.

[Genetic aspects of polycystic ovary syndrome].

Jakubowski L.

Endokrynol Pol. 2005 May-Jun;56(3):285-93. Review. Polish.

PMID:
16350721
20.

The insulin-resistant phenotype of polycystic ovary syndrome.

Svendsen PF, Madsbad S, Nilas L.

Fertil Steril. 2010 Aug;94(3):1052-8. doi: 10.1016/j.fertnstert.2009.04.008. Epub 2009 Jul 5.

PMID:
19580964

Supplemental Content

Support Center